Description
The National Cancer Institute (NCI) is soliciting grant applications for early-stage projects that propose proof-of-concept/pilot studies to test the technical feasibility of innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care. The goal of this funding opportunity is to improve screening and early detection strategies and to develop accurate diagnostic techniques and methods for predicting the course of disease in cancer patients.
Some key aspects of this opportunity include:
• The proposed technologies should have potential for widespread applicability but must be focused on cancer-relevant use cases.
• Projects proposing to apply or use existing technologies for hypothesis-driven research are not responsive to this solicitation.
• The funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
• Applications are due by November 10, 2026, and the earliest start date is April 2027.